E-Posters-10120

10120_Devakumar

Pdf Summary

A study was conducted to assess the safety and effectiveness of IncobotulinumtoxinA (Xeomin) for the treatment of patients with refractory overactive bladder (OAB) symptoms. Currently, the options for patients who fail pharmaceutical management of OAB symptoms include peripheral tibial nerve stimulation, sacral neuromodulation, or intradetrusor botulinum toxin. However, only onabotulinumtoxinA (Botox) is FDA approved for use in OAB patients.<br /><br />The study included a retrospective review of patients who received Xeomin injections for idiopathic, refractory OAB at a single facility between September 2013 and March 2017. Pre and post-procedure outcomes were assessed, including symptoms of incontinence, urinary frequency, nocturia, and post-void residual (PVR), as well as complications.<br /><br />The results showed that Incobotulinumtoxin A was safe and effective for treating idiopathic OAB. Comparisons between IncobotulinumtoxinA and OnabotulinumtoxinA for clinical effectiveness and side effect profiles may be warranted. The treatment success rate was 88%, with significant improvements in urinary frequency, nocturia, and pad usage. Although there was a slight increase in post-injection PVR, it was not significant. Complications within 12 weeks of injection included urinary tract infection (16%) and urinary retention in 1 patient (4%).<br /><br />The study concluded that Xeomin is a potential treatment option for patients with refractory OAB symptoms. Further research comparing Xeomin to Botox for clinical effectiveness and side effects is needed. It is important to note that the study had a small sample size and a relatively short follow-up period. Physicians should consider this off-label use of Xeomin with caution and discuss potential risks and benefits with their patients.

Keywords

IncobotulinumtoxinA

Xeomin

refractory overactive bladder

OAB symptoms

onabotulinumtoxinA

urinary frequency

nocturia

complications

treatment success rate

off-label use